Acquired Squamous Transformation after Long-Term Osimertinib in EGFR-Mutant Lung Adenocarcinoma with Retained EGFR/TP53 Alterations
Acquired squamous histological transformation after long-term osimertinib treatment in EGFR-mutant lung adenocarcinoma with retained EGFR/TP53 alterations.
This case underlines the necessity of re‑biopsy to detect histological transformations in EGFR‑mutant NSCLC, influencing subsequent therapeutic decisions.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT